The opening of the center was held: patients with Still's disease will participate in a phase 3 multicenter study to evaluate the efficacy and safety of GNR-086 compared with Ilaris®, sponsored by GENERIUM Pharmaceutical Company, Russia.
The opening of the center was held: patients with Still's disease will participate in a phase 3 multicenter study to evaluate the efficacy and safety of GNR-086 compared with Ilaris®, sponsored by GENERIUM Pharmaceutical Company, Russia.
